LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy

Authors :: Roy S. Herbst
Enriqueta Felip
Paul Baas
Gregory M. Lubiniecki
Myung-Ju Ahn
Julian R. Molina
Radj Gervais
J-Y. Han
Dong Wook Kim
Mary J. Fidler
G. De Castro
Marcelo Garrido
Yue Shentu
Jose Luis Perez-Gracia
Margarita Majem
Joo Hang Kim
Edward B. Garon
Ellie Im
Source :: Annals of Oncology. 26:ix161
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
medicine.medical_specialty
business.industry
chemistry.chemical_element
Hematology
Pembrolizumab
PD-L1 Positive
Docetaxel
chemistry
Internal medicine
Phase (matter)
Medicine
business
Platinum
medicine.drug

Full Text Access

Tools